Cargando…

Naringenin is a Potential Immunomodulator for Inhibiting Liver Fibrosis by Inhibiting the cGAS-STING Pathway

BACKGROUND AND AIMS: Naringenin is an anti-inflammatory flavonoid that has been studied in chronic liver disease. The mechanism specific to its antifibrosis activity needs further investigation This study was to focused on the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Li, Xia, Siwei, Wang, Shuqi, Zhou, Yuanyuan, Wang, Feixia, Li, Zhanghao, Li, Yang, Kong, Desong, Zhang, Zili, Shao, Jiangjuan, Xu, Xuefen, Zhang, Feng, Zheng, Shizhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: XIA & HE Publishing Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647116/
https://www.ncbi.nlm.nih.gov/pubmed/36406329
http://dx.doi.org/10.14218/JCTH.2022.00120
_version_ 1784827315608354816
author Chen, Li
Xia, Siwei
Wang, Shuqi
Zhou, Yuanyuan
Wang, Feixia
Li, Zhanghao
Li, Yang
Kong, Desong
Zhang, Zili
Shao, Jiangjuan
Xu, Xuefen
Zhang, Feng
Zheng, Shizhong
author_facet Chen, Li
Xia, Siwei
Wang, Shuqi
Zhou, Yuanyuan
Wang, Feixia
Li, Zhanghao
Li, Yang
Kong, Desong
Zhang, Zili
Shao, Jiangjuan
Xu, Xuefen
Zhang, Feng
Zheng, Shizhong
author_sort Chen, Li
collection PubMed
description BACKGROUND AND AIMS: Naringenin is an anti-inflammatory flavonoid that has been studied in chronic liver disease. The mechanism specific to its antifibrosis activity needs further investigation This study was to focused on the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) pathway in hepatic stellate cells and clarified the antifibrosis mechanism of naringenin. METHODS: The relationship between the cGAS-stimulator of interferon genes (STING) pathway and liver fibrosis was analyzed using the Gene Expression Omnibus database. Histopathology, immunohistochemistry, fluorescence staining, Western blotting and polymerase chain reaction were performed to assess gene and protein expression levels associated with the cGAS pathway in clinical liver tissue samples and mouse livers. Molecular docking was performed to evaluate the relationship between naringenin and cGAS, and western blotting was performed to study the expression of inflammatory factors downstream of cGAS in vitro. RESULTS: Clinical database analyses showed that the cGAS-STING pathway is involved in the occurrence of chronic liver disease. Naringenin ameliorated liver injury and liver fibrosis, decreased collagen deposition and cGAS expression, and inhibited inflammation in carbon tetrachloride (CCl(4))-treated mice. Molecular docking found that cGAS may be a direct target of naringenin. Consistent with the in vivo results, we verified the inhibitory effect of naringenin on activated hepatic stellate cells (HSCs). By using the cGAS-specific agonist double-stranded (ds)DNA, we showed that naringenin attenuated the activation of cGAS and its inflammatory factors affected by dsDNA. We verified that naringenin inhibited the cGAS-STING pathway, thereby reducing the secretion of inflammatory factors by HSCs to ameliorate liver fibrosis. CONCLUSIONS: Interrupting the cGAS-STING pathway helped reverse the fibrosis process. Naringenin has potential as an antihepatic fibrosis drug.
format Online
Article
Text
id pubmed-9647116
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher XIA & HE Publishing Inc.
record_format MEDLINE/PubMed
spelling pubmed-96471162022-11-18 Naringenin is a Potential Immunomodulator for Inhibiting Liver Fibrosis by Inhibiting the cGAS-STING Pathway Chen, Li Xia, Siwei Wang, Shuqi Zhou, Yuanyuan Wang, Feixia Li, Zhanghao Li, Yang Kong, Desong Zhang, Zili Shao, Jiangjuan Xu, Xuefen Zhang, Feng Zheng, Shizhong J Clin Transl Hepatol Original Article BACKGROUND AND AIMS: Naringenin is an anti-inflammatory flavonoid that has been studied in chronic liver disease. The mechanism specific to its antifibrosis activity needs further investigation This study was to focused on the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) pathway in hepatic stellate cells and clarified the antifibrosis mechanism of naringenin. METHODS: The relationship between the cGAS-stimulator of interferon genes (STING) pathway and liver fibrosis was analyzed using the Gene Expression Omnibus database. Histopathology, immunohistochemistry, fluorescence staining, Western blotting and polymerase chain reaction were performed to assess gene and protein expression levels associated with the cGAS pathway in clinical liver tissue samples and mouse livers. Molecular docking was performed to evaluate the relationship between naringenin and cGAS, and western blotting was performed to study the expression of inflammatory factors downstream of cGAS in vitro. RESULTS: Clinical database analyses showed that the cGAS-STING pathway is involved in the occurrence of chronic liver disease. Naringenin ameliorated liver injury and liver fibrosis, decreased collagen deposition and cGAS expression, and inhibited inflammation in carbon tetrachloride (CCl(4))-treated mice. Molecular docking found that cGAS may be a direct target of naringenin. Consistent with the in vivo results, we verified the inhibitory effect of naringenin on activated hepatic stellate cells (HSCs). By using the cGAS-specific agonist double-stranded (ds)DNA, we showed that naringenin attenuated the activation of cGAS and its inflammatory factors affected by dsDNA. We verified that naringenin inhibited the cGAS-STING pathway, thereby reducing the secretion of inflammatory factors by HSCs to ameliorate liver fibrosis. CONCLUSIONS: Interrupting the cGAS-STING pathway helped reverse the fibrosis process. Naringenin has potential as an antihepatic fibrosis drug. XIA & HE Publishing Inc. 2023-02-28 2022-04-28 /pmc/articles/PMC9647116/ /pubmed/36406329 http://dx.doi.org/10.14218/JCTH.2022.00120 Text en © 2023 Authors. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Chen, Li
Xia, Siwei
Wang, Shuqi
Zhou, Yuanyuan
Wang, Feixia
Li, Zhanghao
Li, Yang
Kong, Desong
Zhang, Zili
Shao, Jiangjuan
Xu, Xuefen
Zhang, Feng
Zheng, Shizhong
Naringenin is a Potential Immunomodulator for Inhibiting Liver Fibrosis by Inhibiting the cGAS-STING Pathway
title Naringenin is a Potential Immunomodulator for Inhibiting Liver Fibrosis by Inhibiting the cGAS-STING Pathway
title_full Naringenin is a Potential Immunomodulator for Inhibiting Liver Fibrosis by Inhibiting the cGAS-STING Pathway
title_fullStr Naringenin is a Potential Immunomodulator for Inhibiting Liver Fibrosis by Inhibiting the cGAS-STING Pathway
title_full_unstemmed Naringenin is a Potential Immunomodulator for Inhibiting Liver Fibrosis by Inhibiting the cGAS-STING Pathway
title_short Naringenin is a Potential Immunomodulator for Inhibiting Liver Fibrosis by Inhibiting the cGAS-STING Pathway
title_sort naringenin is a potential immunomodulator for inhibiting liver fibrosis by inhibiting the cgas-sting pathway
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647116/
https://www.ncbi.nlm.nih.gov/pubmed/36406329
http://dx.doi.org/10.14218/JCTH.2022.00120
work_keys_str_mv AT chenli naringeninisapotentialimmunomodulatorforinhibitingliverfibrosisbyinhibitingthecgasstingpathway
AT xiasiwei naringeninisapotentialimmunomodulatorforinhibitingliverfibrosisbyinhibitingthecgasstingpathway
AT wangshuqi naringeninisapotentialimmunomodulatorforinhibitingliverfibrosisbyinhibitingthecgasstingpathway
AT zhouyuanyuan naringeninisapotentialimmunomodulatorforinhibitingliverfibrosisbyinhibitingthecgasstingpathway
AT wangfeixia naringeninisapotentialimmunomodulatorforinhibitingliverfibrosisbyinhibitingthecgasstingpathway
AT lizhanghao naringeninisapotentialimmunomodulatorforinhibitingliverfibrosisbyinhibitingthecgasstingpathway
AT liyang naringeninisapotentialimmunomodulatorforinhibitingliverfibrosisbyinhibitingthecgasstingpathway
AT kongdesong naringeninisapotentialimmunomodulatorforinhibitingliverfibrosisbyinhibitingthecgasstingpathway
AT zhangzili naringeninisapotentialimmunomodulatorforinhibitingliverfibrosisbyinhibitingthecgasstingpathway
AT shaojiangjuan naringeninisapotentialimmunomodulatorforinhibitingliverfibrosisbyinhibitingthecgasstingpathway
AT xuxuefen naringeninisapotentialimmunomodulatorforinhibitingliverfibrosisbyinhibitingthecgasstingpathway
AT zhangfeng naringeninisapotentialimmunomodulatorforinhibitingliverfibrosisbyinhibitingthecgasstingpathway
AT zhengshizhong naringeninisapotentialimmunomodulatorforinhibitingliverfibrosisbyinhibitingthecgasstingpathway